{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-060129","form_type":"8-K","ticker":"ASCBF","cik":"0001876716","company_name":"ASPAC II Acquisition Corp.","filed_at":"2023-07-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.962580+00:00","generated_at":"2026-06-13T00:57:29.042879+00:00","sec_items":["7.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"medium","headline":"A SPAC II identifies Taiwan medtech target for potential business combination","bullets":["Target specializes in microsphere tech for ultrasound contrast agents and drug delivery.","First product has passed review to enter Phase 3 trial application with USFDA.","Special meeting on Aug 1, 2023 to vote on extension and other proposals.","Company in preliminary talks to enter non-binding LOI with Partner.","No guarantee definitive agreement will be reached; due diligence ongoing."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-060129","json":"https://secwatch.observer/filing/0001213900-23-060129.json","markdown":"https://secwatch.observer/filing/0001213900-23-060129.md","text":"https://secwatch.observer/filing/0001213900-23-060129.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1876716/000121390023060129/0001213900-23-060129-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1876716/000121390023060129/ea182387-8k_aspac2.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T00:57:29.042879+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}